Source: DGNews  |  Posted 8 years ago

By Maury M. Breecher, PhD, MPH

SAN DIEGO, CA -- May 18, 2003 -- Patients with type 2 diabetes have significantly better fasting plasma glucose levels (FPG) and hemoglobin A1c (HbA1c) levels when treated with metformin combined with repaglinide rather than combined with nateglinide.

Philip Raskin, MD, professor of internal medicine, University of Texas Southwestern at Dallas, Tex, presented these findings here on May 16th during the American Association of Clinical Endocrinologists 12th Annual Meeting and Clinical Congress.

The parallelgroup, randomized, open-label trial, compared the efficacy and safety of repaglinide and nateglinide in combination with metformin for 16 weeks. The group enrolled 192 type 2 diabetic patients with mean ages of 55.9 and 45.3 respectively.

Mean change from baseline HbA1c in the repaglinide patients was